Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2004

View Archived Issues

SBIR grant for IBD research at Adenosine Therapeutics and U. of Virginia

Pivotal trial begins for Procleix West Nile virus blood screening assay

AlzheimAlert test can distinguish vascular cases

Orally active squalene synthase inhibitors against Trypanosoma cruzi

Licorice derivative effective against HIV-1

Suppression of HIV-1 viral replication by p38 MAPK inhibitor

Fully human anti-ICAM antibody effective in murine psoriasis model

6R-BH4 reported to decrease serum phenylalanine levels in PKU patients

PT-141 increases sexual behavior in female rats

Pharmacokinetic profile of IAalpha5-2 in healthy volunteers

Significant survival benefit in A-HeFT study of BiDil brings early conclusion

Plan established with FDA for sBLA filing for Erbitux

Statistically significant increase in growth rate at six months in SomatoKine study

Oral bioavailability of alphaHGA demonstrated

Extension of Neuro3d's research collaboration with Johnson & Johnson

Roche seeks U.S. and E.U. approval for Pegasys in hepatitis B

Juvaris BioTherapeutics in collaborative research agreement with Cell Genesys

Tentative approval for Cipher's CIP-Fenofibrate

Imvamune receives fast track designation

Vical's DNA vaccine for anthrax tested in phase I study

Kahalalide F enters phase II trials in NSCLC and melanoma

Oxcarbazepine found safe and effective in reducing hypersexuality in male AD patients

Dronabinol improves agitation in AD patients

Verbal memory reported to improve with raloxifene in postmenopausal women with AD

CRF antagonists claimed by Roche

TGF-beta inhibitors described in patent literature

Cyclosporins for the treatment of immune disorders

Antiarrhythmic compound from an Indian snake venom

Phenylalanine derivatives for the treatment of diabetes claimed by Merck

Schering claims cannabinoid receptor ligands